Search Results - "Allangba, O."

Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort by Chalopin, T., Macro, M., Decaux, O., Royer, B., Gounot, R., Bobin, A., Karlin, L., Mohty, M., Frenzel, L., Perrot, A., Manier, S., Vincent, L., Dib, M., Slama, B., Richez, V., Allangba, O., Zunic, P., Newinger-Porte, M., Mariette, C., Joly, B., Gay, J., Botoc, I., Malfuson, JV, Garlantezec, R., Hulin, C.

“…Multiple myeloma patients aged 80 years and older are a population more prone to comorbidities and frailty. We aim to describe the real-life management and…”
Get full text

Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA by Marouf, A., Chaubard, S., Michot, J., Liévin, R., Rossignol, J., Golfier, C., Allangba, O., Philippe, L., Tessoulin, B., Chauchet, A., Deau, B., Oberic, L., Vargaftig, J., Moignet, A., Clavert, A., Dulery, R., Brisou, G., Tardy, S., Fataccioli, V., Houot, R., Casasnovas, R., Thieblemont, C., Ghesquières, H., Carras, S., Le Gouill, S., Cartron, G., Marabelle, A., Tournilhac, O., Damaj, G., Gaulard, P., Leval, L., Lemonnier, F., Bachy, E., Hermine, O., Couronné, L., Jaccard, A.

Get full text

P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER by Macro, M., Decaux, O., Perrot, A., Royer, B., Chretien, M., Belhadj, K., Mohty, M., Frenzel, L., Leleu, X., Dib, M., Allangba, O., Zunic, P., Botoc, I., Malfuson, J., Moreau, P., Garlantazec, R., Texier, N., Germain, R., Deal, C., Hulin, C.

Get full text

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial by Moreau, Philippe, Hulin, Cyrille, Macro, Margaret, Caillot, Denis, Chaleteix, Carine, Roussel, Murielle, Garderet, Laurent, Royer, Bruno, Brechignac, Sabine, Tiab, Mourad, Puyade, Mathieu, Escoffre, Martine, Stoppa, Anne-Marie, Facon, Thierry, Pegourie, Brigitte, Chaoui, Driss, Jaccard, Arnaud, Slama, Borhane, Marit, Gerald, Laribi, Karim, Godmer, Pascal, Luycx, Odile, Eisenmann, Jean-Claude, Allangba, Olivier, Dib, Mamoun, Araujo, Carla, Fontan, Jean, Belhadj, Karim, Wetterwald, Marc, Dorvaux, Véronique, Fermand, Jean-Paul, Rodon, Philippe, Kolb, Brigitte, Glaisner, Sylvie, Malfuson, Jean-Valere, Lenain, Pascal, Biron, Laetitia, Planche, Lucie, Caillon, Helene, Avet-Loiseau, Herve, Dejoie, Thomas, Attal, Michel

“…The Intergroupe Francophone du Myélome conducted a randomized trial to compare bortezomib-thalidomide-dexamethasone (VTD) with…”
Get full text

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial by Dumontet, Charles, Hulin, Cyrille, Dimopoulos, Meletios A., Belch, Andrew, Dispenzieri, Angela, Ludwig, Heinz, Rodon, Philippe, Van Droogenbroeck, Jan, Qiu, Lugui, Cavo, Michele, Van de Velde, Ann, Lahuerta, Juan José, Allangba, Olivier, Lee, Jae Hoon, Boyle, Eileen, Perrot, Aurore, Moreau, Philippe, Manier, Salomon, Attal, Michel, Roussel, Murielle, Mohty, Mohamad, Mary, Jean Yves, Civet, Alexandre, Costa, Bruno, Tinel, Antoine, Gaston-Mathé, Yann, Facon, Thierry

“…Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize…”
Get full text

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France by Rey, Jérôme, Viallard, Jean-François, Keddad, Karim, Smith, Jonathan, Wilde, Paul, Kiladjian, Jean-Jacques

“…Objectives To identify switch modalities used when initiating second‐ or third‐line anagrelide for essential thrombocythemia (ET), assess whether anagrelide is…”
Get full text

Mutations MYD88 L265P et CXCR4 WHIM-like dans les neuropathies anti-MAG by Allain, J.S., Pastoret, C., Pihan, M., Allangba, O., Dagorne, A., Doncker, V., Houot, R., Decaux, O.

“…La neuropathie anti-myelin associated glycoprotein (MAG) est une polyneuropathie démyélinisante acquise rare caractérisée par une IgM monoclonale ayant une…”
Get full text

Profil infectieux chez le drépanocytaire by DIOP, S, KOFFI, G, N'DAHTZ, E, ALLANGBA, O, AKA ADJO, M. A, SANOGO, I, SANGARE, A

Get full text

Molecular genetics of glucose-6-phosphate dehydrogenase deficiency in a population of newborns from Ivory Coast by Coulibaly, Foungotin H, Koffi, Gustave, Touré, Honoré A, Bouanga, Jean-Claude, Allangba, Olivier, Tolo, Aïssata, Sawadogo, Duni, Sanogo, Ibrahim, Konaté, Seïdou, Préhu, Claude, Sangaré, Amadou, Galacteros, Frédéric

Get full text

Infection profile in sickle cell anemia by Diop, S, Koffi, G, N'Dahtz, E, Allangba, O, Aka Adjo, M A, Sanogo, I, Sangaré, A

“…Our objectives were to determine aetiology and localisation of infection in sickle cell anaemia patients. The origin of fever was malaria in 47% of cases, 50%…”
Get full text

Epidemiologic, clinical and hematologic profile of K Woolwich hemoglobinopathies in Ivory Coast by Tolo, A, Toure, H A, Elenga, J P, Allangba, O, Sanogo, I, Meite, M, Sangare, A

“…From 1968 to 1992, the hematology laboratory at the University Hospital Center of Abidjan performed 197705 hemoglobin electrophoreses. Isoelectric focusing…”
Get more information

Clinical and hematological profile of Lepore Hemoglobin in Ivory Coast by Sangare, A, Sanogo, I, Meite, M, Segbena, A, Toure, A H, Elenga, J P, Siransy, L, Allangba, O

“…Out of 97320 hemoglobin electrophoreses performed in Abidjan between January 1976 and January 1991, all subjects with hemoglobin Lepore were isolated. This…”
Get more information